CLINICAL_TRIALS ClinicalTrials.gov record update

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax®-AXL-ADC) in Patients With Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02988817
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:02.890124+00:00
Published At: 2023-01-05T00:00:00+00:00
Record Updated At: 2023-08-01
Results Posted At: 2023-01-05
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Thyroid Cancer", "Melanoma", "Sarcoma", "Solid Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-08-01"
protocolSection.identificationModule.nctId: "NCT02988817"
protocolSection.identificationModule.officialTitle: "First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (Enapotamab Vedotin, HuMax\u00ae-AXL-ADC) in Patients With Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-01-05"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.